Activin receptor
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='4bgg' size='340' side='right' caption=' | + | <StructureSection load='4bgg' size='340' side='right' caption='Human Acvr1 kinase domain complex with inhibitor, ethylene glycol and citrate (PDB code [[4bgg]])' scene=''> |
| - | + | ||
== Function == | == Function == | ||
| Line 16: | Line 15: | ||
== Structural highlights == | == Structural highlights == | ||
| - | + | 3D structure of the kinase domain of Acvr1 complex with inhibitor shows the inhibitor forming various interactions with the protein including a hydrogen bond to His residue and a water bridged hydrogen bond to the catalytic lysine<ref>PMID:25101911</ref>. | |
</StructureSection> | </StructureSection> | ||
Revision as of 09:10, 6 May 2020
| |||||||||||
3D structures of activin receptor
Updated on 06-May-2020
References
- ↑ Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013 Oct;45(10):2333-47. doi:, 10.1016/j.biocel.2013.05.019. Epub 2013 May 28. PMID:23721881 doi:http://dx.doi.org/10.1016/j.biocel.2013.05.019
- ↑ Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2017 Sep 12. pii: S8756-3282(17)30340-X. doi: 10.1016/j.bone.2017.09.004. PMID:28918311 doi:http://dx.doi.org/10.1016/j.bone.2017.09.004
- ↑ Roh JD, Hobson R, Chaudhari V, Quintero P, Yeri A, Benson M, Xiao C, Zlotoff D, Bezzerides V, Houstis N, Platt C, Damilano F, Lindman BR, Elmariah S, Biersmith M, Lee SJ, Seidman CE, Seidman JG, Gerszten RE, Lach-Trifilieff E, Glass DJ, Rosenzweig A. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. 2019 Mar 6;11(482). pii: 11/482/eaau8680. doi:, 10.1126/scitranslmed.aau8680. PMID:30842316 doi:http://dx.doi.org/10.1126/scitranslmed.aau8680
- ↑ Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15. doi: 10.1021/jm501177w. Epub 2014 Sep 4. PMID:25101911 doi:http://dx.doi.org/10.1021/jm501177w
